You are here

Press Release Archive

 
- New Ulcerative Colitis Data for XELJANZ® (tofacitinib) at Upcoming Gastroenterology Congresses

Pfizer Inc. (NYSE:PFE) announced today that a total of 10 abstracts on . . .

 
- Pfizer Presents Full Results from Phase 2 Study of Next-Generation Investigational ALK-Inhibitor Lorlatinib in ALK-Positive and ROS1-Positive Advanced Non-Small Cell Lung Cancer

Pfizer Inc. (NYSE:PFE) today announced full results from the Phase 2 clinical trial of the investigational, next-generation tyrosine kinase inhibitor . . .

 
- The Union for International Cancer Control and Pfizer award new round of grants totalling US$500,000 to organisations in 19 countries to address the needs of metastatic breast cancer patients worldwide

This Metastatic Breast Cancer Awareness Day, the Union for International Cancer Control (UICC) and Pfizer Oncology are proud . . .

 
- U.S. FDA Approves LYRICA® CR (pregabalin) Extended-Release Tablets CV

Pfizer Inc. (NYSE: PFE) announced today that the United States Food and Drug Administration (FDA) has approved . . .

 
- Pfizer Reviewing Strategic Alternatives for Consumer Healthcare Business

Pfizer Inc. today announced that it is reviewing strategic alternatives for its Consumer Healthcare business. A range of options will be considered . . .

 
- Pfizer Launches Novel Programs to Put Important Support Services at the Fingertips of Cancer Patients

Pfizer today unveils enhanced offerings to help patients manage their life with cancer. Pfizer Oncology Together . . .

 
- AmerisourceBergen, Blue Cross Blue Shield Association, Pfizer and Prime Therapeutics Join Walgreens to Combat Prescription Drug Abuse by Expanding Safe Medication Disposal Program

Leading health care organizations AmerisourceBergen, Blue Cross Blue Shield Association, Pfizer and Prime Therapeutics are joining Walgreens...

 
- Pfizer Declares 32-Cent Fourth-Quarter 2017 Dividend

The board of directors of Pfizer Inc. today declared a 32-cent fourth-quarter 2017 dividend on the company’s . . .

 
- Bavencio (avelumab) Approved for Merkel Cell Carcinoma in Japan

Merck KGaA, Darmstadt, Germany, and Pfizer Inc. (NYSE: PFE) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved...

 
- Patti LaBelle and Pfizer Work Together to Educate Baby Boomers About the Risk of Pneumococcal Pneumonia

Like many Baby Boomers, award-winning entertainer and music icon Patti LaBelle takes steps to stay healthy . . . 

 
- National Sickle Cell Disease Poll of African Americans Dispels Long-Held Views

Pfizer Inc. (NYSE:PFE), the National Newspaper Publishers Association (NNPA), and scholars from Howard University today announced results ...

 
- New Global Report Finds Majority of People at High Risk of Stroke Not Being Screened for Common Risk Factors

New research released today by The Economist Intelligence Unit (EIU), a division of The Economist...

 
- European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma

Merck KGaA, Darmstadt, Germany, and Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization for BAVENCIO® (avelumab) as a monotherapy for the treatment of . . .

 
- Pfizer Goes To Court To Allow Competition For Biologics And Expand Options For Patients

To ensure patients and providers have access to important, lower cost biosimilar medicines, Pfizer today filed suit in the U.S. District Court for the Eastern District of Pennsylvania against Johnson & Johnson (J&J).

 
- Pfizer Announces Outcome of FDA Advisory Committee Meeting for SUTENT® in Patients at High Risk of Recurrent Renal Cell Carcinoma after Surgery

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration’s (FDA) Oncologic Drug Advisory Committee (ODAC) voted 6 in favor and 6 against the benefit-risk . . .

 
- Pfizer and Astellas Announce Positive Top-Line Results from Phase 3 PROSPER Trial of XTANDI (enzalutamide) in Patients with Non-Metastatic Castration-Resistant Prostate Cancer

Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today that the Phase 3 PROSPER . . .

 
- Pfizer Receives FDA Approval for MYLOTARG™ (gemtuzumab ozogamicin)

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration approved MYLOTARG™ (gemtuzumab ozogamicin) . . .

Pages

Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.

 

Stock Quote Disclaimer

20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.

pdf

If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.